Expertise in
6
conditions

Dr. Kevin J. Bielamowicz

Hematology | Oncology
Arkansas Children's Hospital
1 Childrens Way, 
Little Rock, AR 
Accepting New Patients
18 Years of Experience
Expertise in
6
conditions
Arkansas Children's Hospital
1 Childrens Way, 
Little Rock, AR 

Overview

Kevin Bielamowicz is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. He has been practicing medicine for over 18 years.

Dr. Bielamowicz is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Glioma, Gliomatosis Cerebri, Astrocytoma, and Glioblastoma.

He is actively involved in clinical research, co-authoring 37 peer reviewed articles and participating in 4 clinical trials. Dr. Bielamowicz is currently accepting new patients.

Graduate Year

2008

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in AR

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HMO Partners
  • POS
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Arkansas Children's Hospital
1 Childrens Way, Little Rock, AR 72202

Additional Areas of Focus

Dr. Bielamowicz has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2026
Intervention Type: Drug
Study Drug: Eflornithine
Study Phase: Phase 2
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drug: Mirdametinib
Study Phase: Phase 2
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Carfilzomib, Cyclophosphamide, Etoposide
Study Phase: Phase 1
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Enrollment Status: Terminated
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 1/Phase 2
View 3 Less Clinical Trials

37 Total Publications

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.
A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.
Journal: Cancers
Published: July 31, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Sharmilan Thanendrarajan
Hematology | Oncology
Expertise in
9
conditions
Dr. Sharmilan Thanendrarajan
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (1.8 miles away)
501-526-6990
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

Sharmilan Thanendrarajan is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Thanendrarajan is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
7
conditions
Dr. Jason E. Farrar
Hematology | Oncology
Expertise in
7
conditions
Dr. Jason E. Farrar
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (1.8 miles away)
501-686-5140
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jason Farrar is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Farrar is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Pure Red Cell Aplasia, Aplastic Anemia, Childhood Acute Myeloid Leukemia, and Transient Erythroblastopenia of Childhood. Dr. Farrar is currently accepting new patients.

Expertise in
30
conditions
Dr. Frits Van Rhee
Hematology | Oncology
Expertise in
30
conditions
Dr. Frits Van Rhee
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (1.8 miles away)
501-686-8000
Languages Spoken:
English, Dutch
See accepted insurances
Accepting New Patients
Offers Telehealth

Frits Van Rhee is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Van Rhee is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Van Rhee is currently accepting new patients.

Frequently Asked Questions about Dr. Kevin J. Bielamowicz

How do I make an appointment with Dr. Kevin J. Bielamowicz?

You can book an appointment with Dr. Kevin J. Bielamowicz by calling their office at 501-364-1100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kevin J. Bielamowicz a top-rated expert for Glioma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kevin J. Bielamowicz is classified as an Advanced expert for Glioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kevin J. Bielamowicz specialize in?

While Dr. Kevin J. Bielamowicz is a Hematology, they have specific expertise in Glioma, Gliomatosis Cerebri, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kevin J. Bielamowicz participate in research or clinical trials?

Yes. Dr. Kevin J. Bielamowicz has published 37 articles and abstracts on conditions like Glioma. You can view a list of Dr. Kevin J. Bielamowicz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kevin J. Bielamowicz accept my insurance?

Dr. Kevin J. Bielamowicz accepts most major insurance plans, including Blue Cross Blue Shield and Health Care Services Corporation. We recommend calling the office directly at 501-364-1100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bielamowicz's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile